ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO329

RNA Interference (RNAi) Treatment in Patients With Primary Hyperoxaluria Type 1 on Dialysis: How to Prove Treatment Success?

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Martin Higueras, Cristina, German Hyperoxaluria Center, Bonn, NRW, Germany
  • Torres, Armando, Universidad de La Laguna Facultad de Humanidades, La Laguna, Islas Canarias, Spain
  • Stefanidis, Constantinos J., Mitera Children's Hospital, Athens, Greece
  • Beck, Bodo B., Uniklinik Koln, Koln, Nordrhein-Westfalen, Germany
  • Hoppe, Bernd, German Hyperoxaluria Center, Bonn, NRW, Germany

Primary hyperoxaluria type 1 is a rare genetic disease of glyoxalate metabolism, leading to massively elevated oxalate production in the liver. Concomitant hyperoxaluria induces recurrent kidney stones, or progressive nephrocalcinosis and eventually (early) end stage kidney failure. Two RNA interference medication selectively block endogenous oxalate production. Oxlumo (Alnylam Pharmaceuticals, USA), is authorized for treatment. It blocks glycolate oxidase, reducing oxalate, but increasing glycolate production. Nedosiran (Dicerna/NovoNordisk, Denmark, compassionate use) blocks liver specific LDHA, the final step of oxalate production.


We treated seven patients (age 9-54 years, 4 female) for up to 20 months, with 5 receiving Oxlumo and 2 (the child and a 40-year-old woman) receiving Nedosiran. Dosages provided were according to companies’ recommendations. All but one patient received vitamin B6 (VB6), hemodialysis (HD) regimens were constant. Plasma oxalate (Pox) and glycolate (Pglyc) were measured by ion-chromatography/mass spectrometry at baseline and before every dosage. Speckle echocardiography and bone MRI (3Tesla, left knee) were done at baseline and repeated every 6-8 months.


Pox and PGlyc showed different follow ups: in 2 Oxlumo/VB6 and one Nedosiran/VB6 treated patients Pox was stable, or declined, meanwhile PGlyc increased only in one Oxlumo/VB6 patient (360 µmol/l before 6th dose, normal < 10.3). They only showed, if any, minor systemic oxalate deposits. In all other patients, Pox first decreased, but later fluctuated at high levels (70-130 µmol/l, normal < 7.4). PGlyc increased significantly in all but one Oxlumo, and intermittently in the Nedosiran patient. Lactic acidosis was diagnosed before the 6th Oxlumo dose in the patient without VB6 (PGlyc 1.04 mmol/l). PGlyc further increased to 4.14 mmol/l after the 7th dose. Speckle Echo and bone MRI ameliorated in all, but more rapidly under Nedosiran treatment.


Pox and PGlyc values should be repeatedly controlled in PH 1 HD patients on RNAi treatment. Lactic acidosis can appear in Oxlumo-treated patients with PGlyc values comparable to ethylene glycol intoxication. Pox values remaining elevated do not preclude, that treatment is failing. Imaging procedures then give better evidence of treatment success.


  • Commercial Support